Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Neumora Therapeutics, Inc. Common Stock
NMRACurrent price
10.84 USD
-0.9 USD (-7.67%)
Last closed
11.69 USD
Company
–
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
2 166 779 136 USD
Yield for 12 month
-9.67 %
1Y
3Y
5Y
10Y
15Y
NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. Address: 490 Arsenal Way, Watertown, MA, United States, 02472
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
23.63 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-668 000 USD
Last Year
-2 697 000 USD
Current Quarter
-160 000 USD
Last Quarter
-158 000 USD
Key Figures NMRA
1 year
3 years
5 years
10 years
EBITDA
-230 203 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-37.75 %
PEG Ratio
–
Return On Equity TTM
-77.08 %
Wall Street Target Price
23.63 USD
Revenue TTM
–
Book Value
2.38 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-1.72 USD
Diluted Eps TTM
-1.72 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NMRA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NMRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation NMRA
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-4.6483
Price Book MRQ
5.6832
Financials NMRA
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NMRA
For 52 weeks
8.33 USD
21 USD
50 Day MA
13.02 USD
Shares Short Prior Month
9 681 279
200 Day MA
12.62 USD
Short Ratio
7.62
Shares Short
9 008 776
Short Percent
10.74 %
BeatStart